Reciprocal relationship between plasma ghrelin level and arterial stiffness in hypertensive subjects

Clinical and Experimental Pharmacology and Physiology

Volumn 40, Issue 11, 2013, Pages 735-739

  Zhao, Yin Tao ^a   Yang, Hai Bo ^a   Li, Ling ^a   Gao, Ke ^a   Li, Peng Fei ^a   Xie, Wei Wei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Arterial stiffness; Augmentation index; Circulating ghrelin; Hypertension; Pulse wave velocity

Indexed keywords

GHRELIN; GLUCOSE; HEMOGLOBIN A1C;

ADULT; ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; BRACHIAL ANKLE PULSE WAVE VELOCITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL;

ARTERIAL STIFFNESS; AUGMENTATION INDEX; CIRCULATING GHRELIN; HYPERTENSION; PULSE WAVE VELOCITY;

AGED; ARTERIES; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHINA; CROSS-SECTIONAL STUDIES; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GHRELIN; HOSPITALS, UNIVERSITY; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PULSE WAVE ANALYSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VASCULAR RESISTANCE; VASCULAR STIFFNESS;

EID: 84886789064     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12165     Document Type: Article

References (42)

1. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-analysis. J. Am. Coll. Cardiol. 2010; 55: 1318-27.
2. Laurent S, Alivon M, Beaussier H, Boutouyrie P. Aortic stiffness as a tissue biomarker for predicting future cardiovascular events in asymptomatic hypertensive subjects. Ann. Med. 2012; 44(Suppl. 1): S93-7.
3. Mitchell GF, Hwang SJ, Vasan RS et al. Arterial stiffness and cardiovascular events: The Framingham Heart Study. Circulation 2010; 121: 505-11.
4. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-60.
5. Soares JB, Leite-Moreira AF. Ghrelin, des-acyl ghrelin and obestatin: Three pieces of the same puzzle. Peptides 2008; 29: 1255-70.
6. Li ZF, Guo ZF, Yang SG, Zheng X, Cao J, Qin YW. Circulating ghrelin and ghrelin to obestatin ratio are low in patients with untreated mild-to-moderate hypertension. Regul. Pept. 2010; 165: 206-9.
7. Mager U, Kolehmainen M, Lindstrom J et al. Association between ghrelin gene variations and blood pressure in subjects with impaired glucose tolerance. Am. J. Hypertens. 2006; 19: 920-6.
8. Mizia-Stec K, Zahorska-Markiewicz B, Olszanecka-Glinianowicz M et al. Ghrelin as a potential blood pressure reducing factor in obese women during weight loss treatment. Endokrynol. Pol. 2008; 59: 207-11.
9. Poykko SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of Type 2 diabetes. Diabetes 2003; 52: 2546-53.
10. Sengstock DM, Vaitkevicius PV, Supiano MA. Arterial stiffness is related to insulin resistance in nondiabetic hypertensive older adults. J. Clin. Endocrinol. Metab. 2005; 90: 2823-7.
11. Xu YP, Zhu JJ, Cheng F et al. Ghrelin ameliorates hypoxia-induced pulmonary hypertension via phospho-GSK3 beta/beta-catenin signaling in neonatal rats. J. Mol. Endocrinol. 2011; 47: 33-43.
12. Yano Y, Toshinai K, Inokuchi T et al. Plasma des-acyl ghrelin, but not plasma HMW adiponectin, is a useful cardiometabolic marker for predicting atherosclerosis in elderly hypertensive patients. Atherosclerosis 2009; 204: 590-4.
13. Zhang M, Fang WY, Yuan F et al. Plasma ghrelin levels are closely associated with severity and morphology of angiographically-detected coronary atherosclerosis in Chineses patients with diabetes mellitus. Acta. Pharmacol. Sin. 2012; 33: 452-8.
14. Nagaya N, Kojima M, Uematsu M et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001; 280: R1483-7.
15. Whitworth JA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003; 21: 1983-92.
16. Tesauro M, Schinzari F, Iantorno M et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 2005; 112: 2986-92.
17. Baldanzi G, Filigheddu N, Cutrupi S et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J. Cell. Biol. 2002; 159: 1029-37.
18. Nurnberger J, Keflioglu-Scheiber A. Opazo Saez AM, Wenzel RR, Philipp T, Schafers RF. Augmentation index is associated with cardiovascular risk. J. Hypertens. 2002; 20: 2407-14.
19. Li B, Gao H, Li X, Liu Y, Wang M. Correlation between brachial-ankle pulse wave velocity and arterial compliance and cardiovascular risk factors in elderly patients with arteriosclerosis. Hypertens. Res. 2006; 29: 309-14.
20. Yamashina A, Tomiyama H, Arai T et al. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens. Res. 2003; 26: 615-22.
21. Yasmin, Brown MJ. Similarities and differences between augmentation index and pulse wave velocity in the assessment of arterial stiffness. QJM 1999; 92: 595-600.
22. Kaess BM, Rong J, Larson MG et al. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA 2012; 308: 875-81.
23. Wellcome Trust Case Control Consortiuum. Genome-wide association study of 14 000 cases of seven common diseases and 3000 shared controls. Nature 2007; 447: 661-78.
24. Luft FC. Molecular mechanisms of arterial stiffness: New insights. J. Am. Soc. Hypertens. 2012; 6: 436-8.
25. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 932-43.
26. Gimbrone MA Jr, Garcia-Cardena G. Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis. Cardiovasc. Pathol. 2013; 22: 9-15.
27. Shimizu Y, Nagaya N, Teranishi Y et al. Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochem. Biophys. Res. Commun. 2003; 310: 830-5.
28. Shinde UA, Desai KM, Yu C, Gopalakrishnan V. Nitric oxide synthase inhibition exaggerates the hypotensive response to ghrelin: Role of calcium-activated potassium channels. J. Hypertens. 2005; 23: 779-84.
29. Wiley KE, Davenport AP. Comparison of vasodilators in human internal mammary artery: Ghrelin is a potent physiological antagonist of endothelin-1. Br. J. Pharmacol. 2002; 136: 1146-52.
30. Cardillo C, Kilcoyne CM, Waclawiw M, Cannon RO 3rd, Panza JA. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999; 33: 753-8.
31. Kleinz MJ, Maguire JJ, Skepper JN, Davenport AP. Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man. Cardiovasc. Res. 2006; 69: 227-35.
32. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J. Clin. Invest. 1990; 85: 587-90.
33. Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 2004; 53: 2060-6.
34. Verhaar MC, Strachan FE, Newby DE et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97: 752-6.
35. Wu R, Dong W, Zhou M, Cui X, Hank Simms H, Wang P. Ghrelin improves tissue perfusion in severe sepsis via downregulation of endothelin-1. Cardiovasc. Res. 2005; 68: 318-26.
36. Tesauro M, Schinzari F, Rovella V et al. Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. Hypertension 2009; 54: 995-1000.
37. Zhao H, Liu G, Wang Q et al. Effect of ghrelin on human endothelial cells apoptosis induced by high glucose. Biochem. Biophys. Res. Commun. 2007; 362: 677-81.
38. Li WG, Gavrila D, Liu X et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 2004; 109: 2221-6.
39. Rossi F, Bertone C, Petricca S, Santiemma V. Ghrelin inhibits angiotensin II-induced migration of human aortic endothelial cells. Atherosclerosis 2007; 192: 291-7.
40. Liu J, Lin H, Cheng P, Hu X, Lu H. Effects of ghrelin on the proliferation and differentiation of 3T3-L1 preadipocytes. J. Huazhong Univ. Sci. Technol. Med. Sci. 2009; 29: 227-30.
41. Ueno H, Shiiya T, Mizuta M, Mondal SM, Nakazato M. Plasma ghrelin concentrations in different clinical stages of diabetic complication and glycemic control in Japanese diabetics. Endocr. J. 2007; 54: 895-902.
42. Yildiz BO, Suchard MA, Wong ML, McCann SM, Licinio J. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc. Natl. Acad. Sci. USA 2004; 101: 10434-9.